Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
The inspection was concluded with zero observations
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
Subscribe To Our Newsletter & Stay Updated
